Glenmark Pharmaceuticals Inc., USA, has announced the launch of Vancomycin Hydrochloride for Injection USP in 750 mg/vial, 1.25 g/vial, and 1.5 g/vial (Single-dose vial). The product is bioequivalent and therapeutically equivalent to the reference listed drug from Mylan Laboratories Limited (NDA 209481).
Vancomycin Hydrochloride is a widely used antibiotic for treating serious bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). With this launch, Glenmark expands its presence in the institutional pharmaceutical market.
According to IQVIA™ sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection market generated approximately $39.3 million in annual sales. This highlights the strong demand for the drug in the U.S. healthcare sector.
Marc Kikuchi, President & Business Head, North America, stated, “We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio.”
Glenmark Pharmaceuticals continues to expand its injectable product range, reinforcing its commitment to providing affordable and effective treatments for patients in the United States.
Ahmedabad Plane Crash